Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Santaris Pharma
Woman and Man Max 99 years
Santaris Pharma A/S
Update Il y a 4 ans
A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA
Primary: 1. To determine the MTD of SPC2996 in combination with rituximab in patients with relapsed follicular or lymphoplasmacytic non-Hodgkin’s lymphoma 2. To determine the overall response rate (Co...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Santaris Pharma
Update Il y a 4 ans
Santaris SPC2996-101 : Essai de phase 1, 2 en escalade de dose évaluant l’efficacité et la tolérance d’un traitement par SPC2996 chez des patients ayant une leucémie lymphocytaire chronique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An open-labelled, international, multicenter, dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against BCL-2, in patients with relapsed or refractory chronic lymphocytic leukaem...
Country
France
organs
Leucémies chroniques
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Santaris Pharma A/S
Update Il y a 4 ans
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to Treatment-Naïve Subjects with Chronic Hepatitis C (CHC) Infection
The primary objective of this study is to determine the safety and tolerability of multiple doses of miravirsen in HCV genotype 1 infected subjects
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Santaris Pharma
Update Il y a 4 ans
SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed or refractory Chronic Lymphocytic Leukaemia
To investigate the safety and efficacy of SPC2996 in CLL patients
Country
None
organs
None
Specialty
None
Closed trial
More information